XTSE
CRRX
Market cap144mUSD
Oct 08, Last price
3.30CAD
1D
1.54%
1Q
-5.71%
Jan 2017
-72.03%
IPO
-59.76%
Name
CareRx Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CareRx Corporation, alongside its affiliated entities, delivers specialized pharmaceutical services specifically for Canada's senior population. The company operates a comprehensive network of pharmacy fulfillment centers. These centers are crucial for dispensing chronic medications and offering a variety of other advanced clinical pharmacy solutions. CareRx caters to approximately 50,000 residents across roughly 900 diverse senior living environments, including long-term care facilities, retirement residences, assisted living centers, and communal group homes. Originally established as Centric Health Corporation, the company officially rebranded to CareRx Corporation in June 2020. Tracing its origins back to its incorporation in 2001, CareRx Corporation maintains its primary operational base in Toronto, Canada.
Key people
Suzanne Brand
Chief Financial Officer · since 2024
Puneet Khanna
President, Chief Executive Officer, Director · since 2023
Alpinder Grewal
Senior Vice President - Operations East and Business Transformation · since 2023
Adrianne Sullivan-Campeau
Chief Employee and Customer Experience Officer · since 2024
Raffaele Desando
Director · since 2019
Bruce Moody
Director · since 2020
Independent Director · since 2022
Jeff Watson
Independent Chairman of the Board · since 2024
Legal address
320 Bay Street
Suite 1200
Toronto, ON M5H 4A6
CA
Suite 1200
Toronto, ON M5H 4A6
CA
Headquarters
PO Box 2014
20 Eglinton Avenue West
Suite 2100
Toronto, ON M4R 1K8
CA
20 Eglinton Avenue West
Suite 2100
Toronto, ON M4R 1K8
CA
Previous name
Centric Health Corporation
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||